Farnesyl Transferase Inhibitors

REFERENCES

• Burgoyne R. D. Small GTP-binding proteins. Trends Biochem Sci 1989; 14(10)394–396
   PubMed Web of Science ®Google Scholar
• Chardin P. Small GTP-binding proteins of the ras family: a conserved functional mechanism?. Cancer Cells 1991; 3(4)117–126
   PubMed Web of Science ®Google Scholar
• Downward J. The ras superfamily of small GTP-binding proteins. Trends Biochem Sci 1990; 15(12)469–472
   PubMed Web of Science ®Google Scholar
• Hall A. The cellular functions of small GTP-binding proteins. Science 1990; 249(4969)635–640
   PubMed Web of Science ®Google Scholar
• Takai Y., Sasaki T., Matozaki T. SmaUGTP-bindingproteins. Physiol Rev 2001; 81(1)153–208
   PubMed Web of Science ®Google Scholar
• Takai Y., Kikuchi A., Kawata M., Yamamoto K., Hoshijima M. Purification, characterization, and possible functions of small molecular weight GTP-binding proteins. Am J Hypertens 1990; 3: 220S–223S, (8 Pt 2)
   PubMed Web of Science ®Google Scholar
• Basso A. D., Kirschmeier P., Bishop W. R. Thematic review series: lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 2006; 47(1)15–31
   PubMed Web of Science ®Google Scholar
• Sebti S. M., Hamilton A. D. Inhibition of Ras prenylation: a novel approach to cancer che motherapy. Pharmacol Ther 1997; 74(1)103–114
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Windle J. J., Von Hoff D. D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17(11)3631–3652
   PubMed Web of Science ®Google Scholar
• Sebti S. M., Hamilton A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000; 19(56)6584–6593
   PubMed Web of Science ®Google Scholar
• Thoma N. H., Lakovenko A., Owen D., et al. Phosphoisoprenoid binding specificity of geranylgeranyltransferase type II. Biochemistry 2000; 39(39)12043–12052
   PubMed Web of Science ®Google Scholar
• Lobell R. B., Omer C. A., Abrams M. T., et al. Evaluation of farnesyhprotein transferase and geranylgeranyhprotein transferase inhibitor combinations in preclinical models. Cancer Res 2001; 61(24)8758–8768
   PubMed Web of Science ®Google Scholar
• Cherfils J., Chardin P. GEFs: structural basis for their activation of small GTP-binding proteins. Trends Biochem Sci 1999; 24(8)306–311
   PubMed Web of Science ®Google Scholar
• Paduch M., Jelen F., Otlewski J. Structure of small G proteins and their regulators. Acta Biochim Pol 2001; 48(4)829–850
   PubMed Web of Science ®Google Scholar
• Feinberg A. P., Vogelstein B., Droller M. J., Baylin S. B., Nelkin B. D. Mutation affecting the 12th amino acid of the c-Ha-ras oncogene product occurs infrequently in human cancer. Science 1983; 220(4602)1175–1177
   PubMed Web of Science ®Google Scholar
• Fearon E. R. K-ras gene mutation as a pathogenetic and diagnostic marker in human cancer. J Natl Cancer Inst 1993; 85(24)1978–1980
   PubMed Web of Science ®Google Scholar
• Thor A., Ohuchi N., Hand P. H., et al. Ras gene alterations and enhanced levels of ras p21 expression in a spectrum of benign and malignant human mammary tissues. Lab Invest 1986; 55(6)603–615
   PubMed Web of Science ®Google Scholar
• Rochlitz C. F., Scott G. K., Dodson J. M., et al. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 1989; 49(2)357–360
   PubMed Web of Science ®Google Scholar
• Clark G. J., Der C. J. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 1995; 35(1)133–144
   PubMed Web of Science ®Google Scholar
• Malaney S., Daly R. J. The ras signaling pathway in mammary tumorigenesis and meta stasis. J Mammary Gland Biol Neoplasia 2001; 6(1)101–113
   PubMed Web of Science ®Google Scholar
• Kato S., Masuhiro Y., Watanabe M., et al. Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells 2000; 5(8)593–601
   PubMed Web of Science ®Google Scholar
• Smith C. A., Pollice A. A., Gu L. P., et al. Correlations among p53, Her-2/neu, and ras over-expression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. Clin Cancer Res 2000; 6(1)112–126
   PubMed Web of Science ®Google Scholar
• Bunone G., Briand P. A., Miksicek R. J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. Embo J 1996; 15(9)2174–2183
   PubMed Web of Science ®Google Scholar
• Ikehara N., Semba S., Sakashita M., Aoyama N., Kasuga M., Yokozaki H. BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int J Cancer 2005; 115(6)943–950
   PubMed Web of Science ®Google Scholar
• Kleer C. G., Griffith K. A., Sabel M. S., et al. RhoC-GTPase is a novel tissue biomarker associ ated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 2005; 93(2)101–110
   PubMed Web of Science ®Google Scholar
• Kleer C. G., van Golen K. L., Zhang Y., Wu Z. F., Rubin M. A., Merajver S. D. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002; 160(2)579–584
   PubMed Web of Science ®Google Scholar
• Kleer C. G., Zhang Y., Pan Q., et al. WISPS and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 2004; 6(2)R110–R115
   PubMed Web of Science ®Google Scholar
• van Golen K. L., Davies S., Wu Z. F., et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999; 5(9)2511–2519
   PubMed Web of Science ®Google Scholar
• Gibbs J. B., Oliff A., Kohl N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994; 77(2)175–178
   PubMed Web of Science ®Google Scholar
• Marshall C. J. Cell signalling. Raf gets it together. Nature 1996; 383(6596)127–128
   Google Scholar
• Adjei A. A. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93(14)1062–1074
   PubMed Web of Science ®Google Scholar
• Li T., Sparano J. A. Inhibiting Ras signaling in the therapy of breast cancer. Clin Breast Cancer 2003; 3(6)405–416, discussion 17–20
   PubMedGoogle Scholar
• Wright J. J., Zerivitz K., Gravell A. E., Cheson B. D. Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra). Oncology (Huntingt) 2002; 16(7)930–931
   PubMed Web of Science ®Google Scholar
• Venet M., End D., Angibaud P. Farnesyl protein transferase inhibitor ZARNESTRA R115777—history of a discovery. Curr Top Med Chem 2003; 3(10)1095–1102
   PubMed Web of Science ®Google Scholar
• Johnston S. R. Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol 2001; 2(1)18–26
   PubMedGoogle Scholar
• Caraglia M., Budillon A., Tagliaferri P., Marra M., Abbruzzese A., Caponigro F. Isoprenylation of intracellular proteins as a new target for the therapy of human neo-plasma: preclinical and clinical implications. Curr Drug Targets 2005; 6(3)301–323
   PubMed Web of Science ®Google Scholar
• Johnston S. R., Hickish T., Ellis P., et al. Phase I I study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003; 21(13)2492–2499
   PubMed Web of Science ®Google Scholar
• Johnston S., Semiglazov V., Manikhas G., et al. A randomised, blinded, phase II study of tipi-farnib (Zarnestra) combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. San Antonio Breast Cancer Symposium 2005, (Abstr#5087)
   Google Scholar
• Sparano J. A., Moulder S., Kazi A., et al. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol 2006; 24: 3013–3018
   PubMed Web of Science ®Google Scholar
• End D. W., Smets G., Todd A. V., et al. Characterization of the antitumor effects of the selec tive farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61(1)131–137
   PubMed Web of Science ®Google Scholar
• Pan J., Yeung S. C. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res 2005; 65(20)9109–9112
   PubMed Web of Science ®Google Scholar
• Sepp-Lorenzino L., Rosen N. A farnesyl-protein transferase inhibitor induces p21 expression and Gl block in p53 wild type tumor cells. J Biol Chem 1998; 273(32)20243–20251
   PubMed Web of Science ®Google Scholar
• Ashar H. R., James L., Gray K., et al. The farnesyl transferase inhibitor SCH 66336 induces a G(2) → M or G(1) pause in sensitive human tumor cell lines. Exp Cell Res 2001; 262(1)17–27
   PubMed Web of Science ®Google Scholar
• Le Gouill S., Pellat-Deceunynck C., Harousseau J. L., et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 2002; 16(9)1664–1667
   PubMed Web of Science ®Google Scholar
• Takada Y., Khuri P. R., Aggarwal B. B. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. J Biol Chem 2004; 279(25)26287–26299
   PubMed Web of Science ®Google Scholar
• Xue X., Lai K. T., Huang J. F., Gu Y., Karlsson L., Fourie A. Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib. J Pharmacol Exp Ther 2006; 317: 53–60
   PubMed Web of Science ®Google Scholar
• Pan J., She M., Xu Z. X., Sun L., Yeung S. C. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 2005; 65(9)3671–3681
   PubMed Web of Science ®Google Scholar
• Han J. Y., Oh S. H., Morgillo F., et al. Hypoxia-inducible factor 1 alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005; 97(17)1272–1286
   PubMed Web of Science ®Google Scholar
• Smith V., Rowlands M. G., Barrie E., Workman P., Kelland L. R. Establishment and character ization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res 2002; 8(6)2002–2009
   PubMed Web of Science ®Google Scholar
• Sparreboom A., Marsh S., Mathijssen R. H., Verweij J., McLeod H. L. Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Invest New Drugs 2004; 22(3)285–289
   PubMed Web of Science ®Google Scholar
• Bruzek L. M., Poynter J. N., Kaufmann S. H., Adjei A. A. Characterization of a human carci noma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3, 10-dibromo-6, ll-dihydro-5H-benzo-(5,6)-cyclohepta(l,2-b)-pyridin-ll(R)-yl)-l-piperidinyl)-2-oxo-ethyl)-l-piperidinecarboxamide (SCH66336). Mol Pharmacol 2005; 68(2)477–486
   PubMed Web of Science ®Google Scholar
• Nicholson R. I., Gee J. M. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 2000; 82(3)501–513
   PubMed Web of Science ®Google Scholar
• Katzenellenbogen B. S., Montano M. M., Ekena K., Herman M. E., Mclnerney E. M., William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 1997; 44(1)23–38
   PubMedGoogle Scholar
• Kato S., Endoh H., Masuhiro Y., et al. Activation of the estrogen receptor through phos-phorylation by mitogen-activated protein kinase. Science 1995; 270(5241)1491–1494
   PubMed Web of Science ®Google Scholar
• Cestac P., Sarrabayrouse G., Medale-Giamarchi C., et al. Prenylation inhibitors stimu late both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity. Breast Cancer Res 2005; 7(1)R60–R70
   PubMed Web of Science ®Google Scholar
• Dalenc F., Giamarchi C., Petit M., Poirot M., Favre G., Faye J. C. Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways. Breast Cancer Res 2005; 7(6)R1159–R1167
   PubMed Web of Science ®Google Scholar
• Weinstein-Oppenheimer C. R., Henriquez-Roldan C. F., Davis J. M., et al. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 2001; 7(9)2898–2907
   PubMed Web of Science ®Google Scholar
• Cornwell M. M., Smith D. E. A signal transduction pathway for activation of the rndrl promoter involves the proto-oncogene c-raf kinase. J Biol Chem 1993; 268(21)15347–15350
   PubMed Web of Science ®Google Scholar
• Kim S. H., Lee S. H., Kwak N. H., Kang C. D., Chung B. S. Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett 1996; 98(2)199–205
   PubMed Web of Science ®Google Scholar
• Wang E., Casciano C. N., Clement R. P., Johnson W. W. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res 2001; 61(20)7525–7529
   PubMed Web of Science ®Google Scholar
• Wang E. J., Johnson W. W. The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2. Chemotherapy 2003; 49(6)303–308
   PubMed Web of Science ®Google Scholar
• Rasouli-Nia A., Liu D., Perdue S., Britten R. A. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. Clin Cancer Res 1998; 4(5)1111–1116
   PubMed Web of Science ®Google Scholar
• Izbicka E., Campos D., Carrizales G., Patnaik A. Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro. Anticancer Res 2005; 25(5)3215–3223
   PubMed Web of Science ®Google Scholar
• Marcus A. I., Zhou J., O'Brate A., et al. The synergistic combination of the farnesyl transfer ase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a func tional tubulin deacetylase. Cancer Res 2005; 65(9)3883–3893
   PubMed Web of Science ®Google Scholar
• Zhu K., Gerbino E., Beaupre D. M., et al. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 2005; 105(12)4759–4766
   PubMed Web of Science ®Google Scholar
• Zimmerman T. M., Harlin H., Odenike O. M., et al. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignan cies. J Clin Oncol 2004; 22(23)4816–4822
   PubMed Web of Science ®Google Scholar
• Cortes J. Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome. Curr Hematol Rep 2004; 3(3)157–158
   PubMedGoogle Scholar
• Cortes J., Albitar M., Thomas D., et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003; 101(5)1692–1697
   PubMed Web of Science ®Google Scholar
• Gotlib J. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep 2005; 4(1)77–84
   PubMedGoogle Scholar
• Rao S., Cunningham D., de Gramont A., et al. Phase I II double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004; 22(19)3950–3957
   PubMed Web of Science ®Google Scholar
• Lebowitz P. F., Eng-Wong J., Widemann B. C., et al. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin Cancer Res 2005; 11(3)1247–1252
   PubMed Web of Science ®Google Scholar
• Goss P. E., Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19(3)881–894
   PubMed Web of Science ®Google Scholar
• Ariazi E. A., Ariazi J. L., Cordera F., Jordan V. C. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006; 6(3)195–216
   Web of Science ®Google Scholar
• Carlson R. W., Brown E., Burstein H. J., et al. NCCN task force report: adjuvant therapy for breast cancer. J Natl Compr Cane Net 2006; 4(suppl 1)S1–S26
   PubMedGoogle Scholar
• John Glapsy A. Phase II randomized study of Anastrazole with or without lonafarnib in postmenopausal women with hormone receptor-positive stage IIIB, IIIC or IV breast cancer, http://www.clinicaltrials.gov/ct/show/NCT00098904
   Google Scholar
• Howell A., Robertson J. F., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer pro gressing after prior endocrine treatment. J Clin Oncol 2002; 20(16)3396–3403
   PubMed Web of Science ®Google Scholar
• Osborne C. K., Pippen J., Jones S. E., et al. Double-blind, randomized trial comparing the effi cacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20(16)3386–3395
   PubMed Web of Science ®Google Scholar
• Howell A., Robertson J. F., Abram P., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22(9)1605–1613
   PubMed Web of Science ®Google Scholar
• Vahdat L. T. Phase II study of tipifarnib and fulvestrant as second-line therapy in postmenopausal women with hormone receptor-positive inoperable locally advanced or metastatic breast cancer with progressive disease after prior first-line endocrine therapy, http://www.clinicaltrials.gov/ct/show/NCT00082810
   Google Scholar
• Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15(7)2483–2493
   PubMed Web of Science ®Google Scholar
• Bear H. D., Anderson S., Brown A., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: prelimi nary results from National Surgical Adjuvant Breast and Bowel Project Protocol B–27. J Clin Oncol 2003; 21(22)4165–4174
   PubMed Web of Science ®Google Scholar
• Guarneri V., Broglio K., Kau S. W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24(7)1037–1044
   PubMed Web of Science ®Google Scholar
• Citron M. L., Berry D. A., Cirrincione C., et al. Randomized trial of dose-dense versus con ventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21(8)1431–1439
   PubMed Web of Science ®Google Scholar
• William Gradishar J. Phase II study of capecitabine and tipifarnib in women with taxane-resistant metastatic breast cancer, http://www.clinicaltrials.gov/ct/show/NCT00077363
   Google Scholar
• Banu Arun. Phase I/II study of tipifarnib and gemcitabine in women with metastatic breast cancer, http://www.clinicaltrials.gov/ct/show/NCT00100750
   Google Scholar
• Jan H. M. Schellens. Phase I study of lonafarnib, trastuzumab (herceptin—®), and paclitaxel in patients with HER2/Neu-overexpressing stage IIIB, IIIC, or IV breast cancer, http://www.clinicaltrials.gov/ct/show/NCT00068757
   Google Scholar
• Van Cutsem E., van de Velde H., Karasek P., et al. Phase III trial of gemcitabine plus tipi farnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22(8)1430–1438
   PubMed Web of Science ®Google Scholar
• Meier Werner, http://www.clinicaltrials.gov/ct/show/NCT00281515 An open-label, multicenter, randomized phase II study to compare the effects of paclitaxel/carboplatin and lonafarnib to those of paclitaxel/carboplatin for first-line treatment of patients with epithelial ovarian cancer FIGO stages IIB-IV
   Google Scholar
• http://www.clinicaltrials.gov/ct/show/NCT00109538 Schering-Plough. A pivotal randomized study of lonafarnib versus placebo in the treatment of subjects with myelodysplastic syndrome (MDS) or chronic myelomonocytic leu kemia (CMML) who are platelet transfusion dependent with or without anemia
   Google Scholar
• Adjei A., Croghan G. A., Erlichman C., et al. A phase I trial of the farnesyltransferase inhibi tor R115777, in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 2003; 9: 2520–2526
   PubMed Web of Science ®Google Scholar
• Kelland L. R., Smith V., Valenti M., et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 2001; 7(11)3544–3550
   PubMed Web of Science ®Google Scholar
• Britten C. D., Rowinsky E. K., Soignet S., et al. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin Cancer Res 2001; 7(12)3894–3903
   PubMed Web of Science ®Google Scholar
• Haas N., Peereboom D., Ranganathan S., Thistle A., Greenberg R., Ross E., Lewis N., Wright J., Hudes G. Phase II trial of R115777, an inhibitor of farnesyltransferase, in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2002; 21, (abstract 271)
   Google Scholar
• Adjei A. A., Davis J. N., Erlichman C., Svingen P. A., Kaufmann S. H. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 2000; 6(6)2318–2325
   PubMed Web of Science ®Google Scholar
• Moasser M. M., Rosen N. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer. Breast Cancer Res Treat 2002; 73(2)135–144
   PubMed Web of Science ®Google Scholar
• Hu W., Wu W., Verschraegen C. F., et al. Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. Proteomics 2003; 3(10)1904–1911
   PubMed Web of Science ®Google Scholar
• Raponi M., Belly R. T., Karp J. E., Lancet J. E., Atkins D., Wang Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 2004; 4(56)1–12, http://www.biomedcentral.com/1471-2407/4/56
   PubMedGoogle Scholar